Skip to main content

Table 3 Multivariable Cox regression analyses of variables correlated with clinical outcomes on the patients with locally advanced rectal cancer

From: Preoperative chemoradiotherapy with capecitabine and triweekly oxaliplatin versus capecitabine monotherapy for locally advanced rectal cancer: a propensity-score matched study

 

Distant metastasis-free survival

Overall survival

Disease-free survival

P

HR (95%CI)

P

HR (95%CI)

P

HR (95%CI)

Unadjusted cohort

 Gender

0.035*

0.729 (0.543–0.978)

0.348

0.859 (0.626–1.180)

0.144

0.820 (0.628–1.070)

 Age

0.674

0.937 (0.693–1.267)

0.165

1.247 (0.913–1.702)

0.797

1.036 (0.792–1.355)

 cT stage

0.500

0.918 (0.715–1.178)

0.757

0.959 (0.733–1.254)

0.929

1.010 (0.806–1.266)

 cN stage

0.309

0.758 (0.445–1.292)

0.821

1.074 (0.580–1.986)

0.286

0.772 (0.480–1.242)

 Pretreatment CEA

0.072

1.265 (0.979–1.634)

0.076

1.284 (0.975–1.691)

0.110

1.208 (0.958–1.523)

 Type of radiation

0.673

1.073 (0.772–1.492)

0.836

0.962 (0.668–1.386)

0.849

0.970 (0.707–1.330)

 Concurrent chemotherapy

0.871

0.973 (0.695–1.361)

0.682

1.073 (0.765–1.506)

0.820

0.967 (0.724–1.291)

 Adjuvant chemotherapy

0.112

1.379 (0.927–2.052)

0.814

0.954 (0.641–1.418)

0.182

1.265 (0.896–1.786)

 pCR

0.796

1.119 (0.477–2.626)

0.003*

3.634 (1.532–8.623)

0.160

1.648 (0.820–3.312)

 ypT stage

< 0.001*

2.066 (1.598–2.670)

< 0.001*

1.902 (1.497–2.417)

< 0.001*

1.770 (1.431–2.188)

 ypN stage

< 0.001*

1.768 (1.439–2.172)

< 0.001*

2.048 (1.639–2.558)

< 0.001*

1.941 (1.615–2.331)

 RCRG

0.817

0.992 (0.923–1.066)

0.133

1.050 (0.985–1.120)

0.287

1.031 (0.975–1.091)

PS-adjusted cohort

 Gender

0.414

0.854 (0.584–1.248)

0.923

1.021 (0.666–1.565)

0.510

0.893 (0.636–1.252)

 Age

0.856

1.036 (0.707–1.519)

0.029*

1.562 (1.047–2.330)

0.291

1.196 (0.858–1.668)

 cT stage

0.629

0.921 (0.660–1.285)

0.492

1.138 (0.787–1.643)

0.591

1.086 (0.804–1.466)

 cN stage

0.469

0.773 (0.385–1.551)

0.768

1.127 (0.508–2.500)

0.828

0.932 (0.494–1.758)

 Pretreatment CEA

0.011*

1.526 (1.101–2.116)

0.013*

1.578 (1.100–2.263)

0.013*

1.447 (1.081–1.937)

 Type of radiation

0.438

1.182 (0.775–1.802)

0.492

1.169 (0.749–1.825)

0.712

1.072 (0.743–1.546)

 Concurrent chemotherapy

0.855

0.964–0.651-1.429)

0.482

1.163 (0.764–1.769)

0.775

0.950 (0.670–1.348)

 Adjuvant chemotherapy

0.040*

1.771 (1.027–3.053)

0.919

1.027 (0.612–1.724)

0.194

1.338 (0.862–2.077)

 pCR

0.383

0.623 (0.215–1.804)

0.256

1.864 (0.636–5.466)

0.960

1.022 (0.443–2.359)

 ypT stage

0.001*

1.701 (1.240–2.334)

0.037*

1.430 (1.023–2.000)

0.005*

1.459 (1.121–1.899)

 ypN stage

< 0.001*

1.903 (1.457–2.487)

< 0.001*

2.253 (1.680–3.022)

< 0.001*

2.023 (1.594–2.566)

 RCRG

0.577

1.027 (0.935–1.129)

0.243

1.056 (0.964–1.157)

0.365

1.037 (0.959–1.122)

  1. HR Hazard ratio, CI Confidence interval, pCR Pathological complete response, RCRG Rectal cancer regression grade, PS Propensity score. * P < 0.05